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Background: We evaluated the performance of multiplex tandem mass spectrometry (MS/MS) in newborn screening for detection 
of 6 lysosomal storage disorders (LSDs), namely, Niemann-Pick A/B, Krabbe, Gaucher, Fabry, and Pompe diseases and Hurler syn-
drome. 
Methods: We revised the conditions and procedures of multiplex enzyme assay for the MS/MS analysis and determined the preci-
sion of our enzyme assay and the effects of sample amounts and incubation time on the results. We also measured the degree of 
correlation between the enzyme activities in the dried blood spots (DBSs) and those in the leukocytes. DBSs of 211 normal new-
borns and 13 newborns with various LSDs were analyzed using our revised methods.
Results: The intra- and inter-assay precisions were 2.9-18.7% and 8.1-18.1%, respectively. The amount of product obtained was pro-
portional to the DBS eluate volume, but a slight flattening was observed in the product vs. sample volume curve at higher sample 
volumes. For each enzyme assay, the amount of product obtained increased linearly with the incubation period (range, 0-24 hr). 
Passing and Bablok regression analysis revealed that the enzyme activities in the DBSs and those in the leukocytes were favorably 
correlated. The enzyme activities measured in the DBSs were consistently lower in patients with LSDs than in normal newborns.
Conclusions: The performance of our revised techniques for MS/MS detection and enzyme assays was of the generally acceptable 
standard. To our knowledge, this is the first report on the use of MS/MS for newborn screening of LSDs in an Asian population.
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INTRODUCTION
A lysosome is an intracellular organelle containing nu-
merous acid hydrolases that degrade biological molecules 
such as proteins, glycoproteins, proteoglycans, lipids, and 
other complex macromolecules. Lysosomal storage disor-
ders (LSDs) are caused by loss-of-function mutations in the 
genes encoding for lysosomal hydrolases; these mutations 
lead to the accumulation of intermediate metabolic prod-
ucts [1]. More than 40 different LSDs are known, and the 
incidence of all LSDs is about 1:7,000-1:9,000 [2]. LSDs are 
usually diagnosed by performing assays for the enzyme of 
interest by using an artificial substrate with a fluorescent tag 
such as 4-methylumbelliferone.
The use of tandem mass spectrometry (MS/MS) in new-
born screening programs has improved the detection of in-
born errors of metabolism, and this technique can be ap-
plied to a wide range of metabolites [3-6]. MS/MS screening 
for LSDs was first described by Li et al. [7]; they performed 
direct multiplex assays for Fabry, Gaucher, Krabbe, Niemann-
Pick A/B, and Pompe diseases by using dried blood spots 
(DBS). A refined method for high-throughput analysis by 
using MS/MS at a newborn screening laboratory was repor-
ted by Zhang et al. [8]. The findings of these studies demon-
strated the usefulness of MS/MS in newborn screening for 
LSDs.
Mucopolysaccharidoses (MPSs) are a group of LSDs. In Han M, et al.  •  Use of MS/MS for Newborn Screening of LSDs 
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individuals with MPS, deficiency or malfunction of specific 
lysosomal enzymes leads to an abnormal accumulation of 
certain complex carbohydrates such as mucopolysaccha-
rides or glycosaminoglycans. MPSs have several different 
types and subtypes. Since the symptoms of MPS may not be 
recognized early in life, the diagnosis of MPS is challenging, 
and its early detection is necessary. MS/MS techniques for 
detecting MPS on the basis of DBSs have been developed 
for some MPSs such as Hurler syndrome (MPS I), Hunter 
syndrome (MPS II), Maroteaux-Lamy syndrome (MPS VI), 
and Morquio syndrome type A (MPS IVA) [9-15].
In this study, we performed a revised multiplex MS/MS 
technique for newborn screening of 6 LSDs, namely, Nie-
mann-Pick A/B, Krabbe, Gaucher, Fabry, and Pompe dis-
eases, and MPS I. Although several cases of LSDs in the Ko-
rean population have been reported, the incidence and prev-
alence of LSDs in Korea is unknown. To our knowledge, this 
is the first report on the use of MS/MS for newborn screen-
ing of LSDs in a Korean population. Further, we evaluated 
the potential of our revised techniques for future use in new-
born screening programs.
MATERIALS AND METHODS
1. Materials
HPLC-grade methanol (Burdick & Jackson, Muskegon, 
MI, USA) and water (Mallinckrodt Baker, Phillipsburg, NJ, 
USA) were used. The enzymes, substrates (S), and internal 
standards (IS) used to test for various diseases were as fol-
lows: acid sphingomyelinase (ASM), ASM-S, and ASM-IS 
for Niemann-Pick A/B disease; galactocerebrosidase, GALC-
S, and GALC-IS for Krabbe disease; acid β-glucocerebro-
sidase (ABG), ABG-S, and ABG-IS for Gaucher disease; acid 
α-galactosidase (GLA), GLA-S, and GLA-IS for Fabry dis-
ease; acid α-glucosidase (GAA), GAA-S, and GAA-IS for 
Pompe disease; and α-L-iduronidase (IDU), IDU-S, and 
IDU-IS for MPS I. All reagents were kindly donated by Gen-
zyme Pharmaceuticals (Cambridge, MA, USA) through the 
Centers for Disease Control and Prevention (CDC, USA). 
All the other reagents were of research grade or better qual-
ity and were purchased from Sigma Chemical Co. (St. Louis, 
MO, USA). This research was approved by the Institutional 
Review Board of the Seoul National University Bundang 
Hospital.
2. Enzyme assay procedures
All the procedures, including those for preparing the as-
say buffer and assay cocktail and for conducting the enzyme 
assay, were performed after modifying the methods devel-
oped by Zhang et al. [8] and Duffey et al. [12]. For prepar-
ing the GAA assay cocktail, 1.8 mL of a 100 g/L solution of 
3-[(3-cholamidopropyl) dimethylammonio]-1-propanesul-
fonate in water, 15.9 mL of 0.3 mol/L citrate-phosphate buf-
fer, and 0.3 mL of a 8 mmol/L solution of acarbose in water 
were added to a vial containing GAA-S/IS. The GLA assay 
cocktail was prepared by adding 0.45 mL of a 120 g/L solu-
tion of sodium taurocholate in water, 14.67 mL of 0.174 mol/
L sodium acetate buffer, and 2.88 mL of 1 mol/L solution of 
N-acetylgalactosamine in water to a vial containing GLA-S/
IS. The ABG assay cocktail consisted of 2.4 mL of a 120 g/L 
solution of sodium taurocholate in water and 15.6 mL of 
0.62 mol/L citrate-phosphate buffer in a vial containing ABG-
S/IS. For preparing the ASM assay cocktail, 0.15 mL of a 
120 g/L solution of sodium taurocholate in water, 17.85 mL 
of 0.92 mol/L sodium acetate buffer, and 0.151 mL of 0.1 
mol/L zinc chloride were added to a vial containing ASM-
S/IS. The GALC assay cocktail was prepared by adding 1.8 
mL of a solution containing 96 g/L sodium taurocholate 
with 12 g/L oleic acid in water and 16.2 mL of 0.18 mol/L 
citrate-phosphate buffer to a vial containing GALC-S/IS. 
For preparing the IDU assay cocktail, 9.9 mL of 0.1 mol/L 
ammonium formate buffer was added to a vial containing 
IDU-S/IS.
We punched out 2 DBS disks of 3.2-mm diameter (con-
taining approximately 6.4 μL of dried blood) from each card. 
One disk was placed in a 96-well plate for the GALC assay, 
and the other disk was placed on a plate containing 70 μL of 
sodium phosphate elution buffer and then mixed on an or-
bital shaker for 1 hr at 250 rpm and 37°C. Each enzyme cock-
tail (15 μL), except the GALC assay cocktail, was added to a 
separate plate, and 10 μL of this DBS extract was added to 
it. The GALC assay cocktail (30 μL) was added to the GALC 
assay plate. All the plates were incubated on an orbital shaker 
at 225 rpm and 37°C for 15 hr. After the reactions were com-
plete, they were quenched with 100 μL of ethyl acetate-meth-
anol (1:1) solution. We used ethyl acetate within 1 week of 
opening the reagent container. Next, we added 400 μL of 
both ethyl acetate and water to the plate, transferred 300 μL 
of the top organic layer to a deep-well plate, and then dried 
this plate under N2 gas. The dried extract was resuspended 
in a 100 μL of ethyl acetate-methanol (19:1) solution. Next, 
100 mg of silica gel was loaded in the well of the plate, and 
250 μL of ethyl acetate-methanol (19:1) solution was added 
for washing. The resuspended extract was then poured on a 
filter plate, and it was washed thrice with 400 μL of ethyl ac-
etate-methanol (19:1) solution by using a microplate vac-
uum filtration apparatus. After drying the plate under N2 
gas, the extract was resuspended in 100 μL of the mobile 252     www.kjlm.org
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phase (80% acetonitrile, 20% water containing 0.2% formic 
acid) for MS.
3. Electrospray ionization-MS/MS
Electrospray ionization (ESI)-MS/MS was performed us-
ing a Waters Quattro Premier XE tandem mass spectrome-
ter (Waters, MA, USA) in a positive-ion, multiple-reaction 
monitoring mode and by flow injection [8]. We injected 10 
µL of the resuspended sample into the Waters ACQUITY 
ultra-performance liquid chromatographic system at an in-
jection rate of 0.1 mL/min for 1.10 min and then at a rate of 
0.5 mL/min for 0.4 min. The conditions used for the MS/
MS are stated in detail in Table 1.
The amount of product was calculated by multiplying the 
ratio of ion abundance of the product to that of the internal 
standard (obtained after subtracting the values for the blank 
from those for the samples) with the amount of the added 
internal standard and then dividing the value by the ratio of 
the response factor of the product to that of the internal stan-
dard. The response factor was calculated from the calibra-
tion curves obtained for the standards containing ratios of 
product and internal standard. The enzyme activities were 
expressed in μmol/h/L and were calculated from the amount 
of product by assuming that a 3.2-mm DBS disk contained 
3.2 μL of blood.
4. Determination of precision
Intra-assay precisions (intra-assay CVs) were determined 
by performing 6 replicated assays for the CDC QC samples 
at concentrations that showed medium and high activity. To 
evaluate the inter-assay CVs, enzyme activities of the same 
CDC samples were measured on 7 consecutive days. 
5. Effect of Sample amount and incubation time
To evaluate whether the product obtained in the reaction 
is linearly related to the amount of enzyme used in the as-
say, we measured the enzyme activities for 5 μL, 10 μL, and 
20 μL of DBSs eluates. Each eluate was analyzed twice. To 
assess the effect of incubation time, the enzyme reactions 
were monitored at fixed intervals over 24 hr (0, 4, 8, and 24 
hr). Each eluate was analyzed twice.
6. Enzyme activities in DBSs and leukocytes
To evaluate the correlation between the enzyme activities 
in the DBSs and in the leukocytes, we measured the activity 
of each enzyme (GALC, ABG, GLA, GAA, and IDU) in both 
DBSs and leukocytes. Lysosomal enzyme activities in the 
leukocytes were determined by using appropriate fluoro-
genic substrates and commonly used methods. Enzyme ac-
tivities were expressed as nmole of cleaved substrate per mil-
ligram of protein per hour at 37°C. Passing and Bablok re-
gression analysis was performed for comparison analysis.
7. DBSs of patients and normal individuals
To validate the capability of our system to detect LSDs in 
newborns, we analyzed DBSs from 4 patients with Krabbe 
disease, 1 patient with Gaucher disease, 1 patient with Fabry 
disease, 6 patients with Pompe disease, and 1 patient with 
MPS I. All these patients were previously diagnosed to have 
the respective diseases on the basis of their clinical symptoms 
and findings of established biochemical tests.
Enzyme activities in the DBSs obtained from 211 new-
borns without any enzymatic abnormalities were measured 
as controls.
RESULTS
1. Precision
The intra-assay CVs for ASM were 7.7% and 8.5%, for 
GALC were 4.7% and 2.9%, for ABG were 12.4% and 6.7%, 
for GLA were 12.0% and 11.6%, for GAA were 6.9% and 
5.2%, and for IDU were 18.7% and 8.8% at medium and high 
concentrations of the enzymes, respectively. Compared to 
the intra-assay CVs, the inter-assay CVs were greater; the 
inter-assay CVs for ASM were 9.1% and 16.0%, for GALC 
were 9.1% and 11.8%, for ABG were 15.4% and 11.1%, for 
GLA were 18.1% and 16.3%, for GAA were 10.0% and 8.1%, 
and for IDU were 17.5% and 16.4% at medium and high 
Table 1. Conditions for tandem mass spectrometry and multiple reaction 
monitoring (MRM) transitions of the products and internal standards.
Cone voltage (V) Collision energy (eV) MRM Transition (m/z)
ASM-P 19 20 398→264
ASM-IS 19 20 370→264
GALC-P 21 22 426→264
GALC-IS 21 22 454→264
ABG-P 22 26 482→264
ABG-IS 22 25 510→264
GLA-P 17 14 484→384
GLA-IS 17 14 489→389
GAA-P 21 14 498→398
GAA-IS 22 15 503→403
IDU-P 12 12 391→291
IUD-IS 12 12 377→277
Abbreviations: P, product; IS, internal standard; ASM, acid sphingomyelinase (Niemann-
Pick A/B disease); GALC, galactocerebrosidase (Krabbe disease); ABG, acid β-gluco-
cerebrosidase (Gaucher disease); GLA, acid α-galactosidase (Fabry disease); GAA, acid 
α-glucosidase (Pompe disease); IDU, α-L-iduronidase (Hurler disease).Han M, et al.  •  Use of MS/MS for Newborn Screening of LSDs 
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concentrations of the enzymes, respectively.
2. Effect of sample amount and incubation time
The amount of product obtained was proportional to the 
volume of the eluate used in the assay, but a slight flattening 
was observed in the product vs. sample volume curve at higher 
sample volumes, especially for GALC (Fig. 1). Zhang et al. 
[8] reported similar results, and they suggested that the ob-
served flattening of the curve maybe attributable to the pre-
sence of 1 or more inhibitors in the DBSs; an increased elu-
ate volume would lead to an increased inhibitor-to-substrate 
ratio.
In each enzyme assay, the amount of product obtained 
increased linearly with the incubation period (Fig. 2). We 
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Fig. 1. Effect of sample amount on enzyme activity. Representative graphs for the 6 enzyme assays with respect to the added volume of DBS eluate.
Abbreviations: ASM, acid sphingomyelinase (Niemann-Pick A/B disease); GALC, galactocerebrosidase (Krabbe disease); ABG, acid β-glucocerebrosidase (Gaucher 
disease); GLA, acid α-galactosidase (Fabry disease); GAA, acid α-glucosidase (Pompe disease); and IDU, α-L-iduronidase (Hurler disease).
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determined 15 hr of incubation as optimal, and used this in-
cubation time for all subsequent enzyme assays.
3. Enzyme activities in DBSs and leukocytes
Passing and Bablok regression analysis revealed that the 
enzyme assay in DBSs and leukocytes compared favorably 
(Fig. 3).
4.   Enzyme activities in DBSs of patients and normal 
newborns
The enzyme activities in the DBSs of normal newborns 
and patients are shown in Fig. 4. As expected, the enzyme 
activities in the DBSs of patients were consistently lower 
than those in the DBSs of normal newborns; the values for 
the enzyme activities did not overlap. From these findings, 
we determined the following cut-off points for each enzyme 
in order to discriminate between normal newborns and pa-
tients: 0.45 μmol/h/L for Krabbe disease, 5.74 μmol/h/L for 
Gaucher disease, 1.31 μmol/h/L for Fabry disease, 2.90 μmol/ 
h/L for Pompe disease, and 7.20 μmol/h/L for MPS I.
DISCUSSION
Since the MS/MS techniques were developed for newborn 
screening of LSDs, several methods for multiplex MS/MS 
have been introduced; however, the maximum number of 
diseases reported to be diagnosed by using multiplex MS/
MS is 5 [7, 8]. To our knowledge, this is the first study that 
reports the feasibility of multiplex MS/MS for diagnosing 6 
LSDs, including MPS I, in newborns. The assay performance 
for our revised method in terms of precision, optimal incu-
bation time, and required sample amounts was of the gen-
erally acceptable standard. For each of the 6 enzymes, the 
assays enabled unambiguous differentiation between sam-
ples obtained from healthy newborns and patients (Fig. 4), 
suggesting that our method for multiplex MS/MS was effec-
tive for newborn screening of LSDs in the Korean popula-
tion.
A limitation of this study is that only a small number of 
DBSs were obtained from patients with Krabbe, Pompe, 
Gau  cher, and Fabry diseases and MPS I and that no DBS 
could be obtained for Niemann-Pick disease leading to a 
lack of data for this disease. However, we measured the en-
zyme activities in QC DBSs obtained from the CDC, and 
our results correlate well with those reported by the CDC 
(data not shown).
Diagnosis of LSD is usually confirmed by performing an 
enzyme assay for leukocyte samples by using fluorogenic 
Fig. 3. Passing and Bablok regression analysis for the lysosomal enzyme activities in the DBSs and leukocytes.
Abbreviations: GALC, galactocerebrosidase (Krabbe disease); ABG, acid β-glucocerebrosidase (Gaucher disease); GLA, acid α-galactosidase (Fabry disease); GAA, 
acid α-glucosidase (Pompe disease); and IDU, α-L-iduronidase (Hurler disease).
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Fig. 4. Comparison of enzyme activities in DBSs from healthy newborns (n=211) and patients with LSDs (4 patients with Krabbe disease, 1 patient with Gaucher 
disease, 1 patient with Fabry disease, 6 patients with Pompe disease, and 1 patient with Hurler syndrome).
Abbreviations: ASM, acid sphingomyelinase (Niemann-Pick A/B disease); GALC, galactocerebrosidase (Krabbe disease); ABG, acid β-glucocerebrosidase (Gaucher 
disease); GLA, acid α-galactosidase (Fabry disease); GAA, acid α-glucosidase (Pompe disease); and IDU, α-L-iduronidase (Hurler disease).
substrates (such as 4-methylumbelliferone). Therefore, it is 
important that the enzyme activities measured in the DBSs 
correlate with those measured in the leukocytes. Although 
several studies on MS/MS detection of LSD enzymes have 
been reported [7-15], these studies evaluated enzyme activi-
ties only in DBSs; to date, no studies on the correlation be-
tween the enzyme activities in the DBSs and those in the 
leukocytes have been performed. We evaluated the correla-
tion between the enzyme activities measured in the DBSs 
and leukocyte (Fig. 3) and found a good correlation; this 
indicates that our screening tests on the DBSs of newborns 
reflect the original characteristics of the blood sample.
The incidence of LSDs in the Korean population is not 
known. On the basis of our experience in the field of bio-
chemical diagnosis of LSDs, we think that Krabbe, Gaucher, 
Pompe, and Fabry diseases and MPS I occur frequently. How-
ever, Niemann-Pick A/B disease is rare. Therefore, it is not 
cost-effective to screen for Niemann-Pick disease in Korea. 
Other LSDs such as metachromatic leukodystrophy (MLD, 
defect in arylsulfatase A) and MPS-II (defect in iduronate 
sulfatase) are relatively common in Korea. Therefore, the 
diseases included in the group diagnosed by multiplex MS/
MS for newborn screening of LSDs in Korea should be chan-
ged. We are now developing methods for measuring aryl-
sulfatase A and iduronate sulfatase activities in DBSs by us-
ing MS/MS. Our goal is to replace Niemann-Pick disease 
with MLD and/or MPS-II in the Korean newborn screen-
ing program for LSDs.
In conclusion, we evaluated the performance of MS/MS 
in a newborn screening for LSDs and found the performance 
to be of the generally acceptable standard. To our knowledge, 
this is the first report of the use of MS/MS in newborn screen-
ing of LSDs in an Asian population.
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